Switching factor products: selecting patients and managing the process

Harrington, Christine; Hay, C. R. M.; Vidler, Vicky; Dattani, Rashesh; Heygate, Katherine M.

doi:10.17225/jhp.00021

Cited by 2 publications

(3 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Patients should be made aware of the options open to them as the final decision to switch factor product is often made by the patient. Occasionally, changes in tender systems will also change a product's availability, necessitating a switch for some patients [82]. The role of the health-care professional is to educate and help manage the emotional welling of a patient to ensure that the patient makes well-informed decisions.…”

Section: Factors To Address Before Switching Patientsmentioning

confidence: 99%

“…Unrealistic expectations can negatively affect a patient's outcomes and patients expecting significantly greater bleed protection may initiate high levels of physical activity, or engage in high-risk activities that could lead to increased rates of traumatic bleeds. A patient's goals may indicate whether their expectations are realistic [1,82].…”

Section: Factors To Address Before Switching Patientsmentioning

confidence: 99%

See 1 more Smart Citation

Switching patients in the age of long-acting recombinant products?

Escobar¹,

Santagostino

Mancuso

et al. 2019

Expert Review of Hematology

View full text Add to dashboard Cite

Introduction: Prophylaxis with factor replacement therapy is the gold standard for the treatment of hemophilia, but this often requires frequent infusions. A number of long-acting factor products have been developed to reduce the burden on patients. Areas covered: This is an overview of information presented at two symposia held at the World Federation of Hemophilia and International Society on Thrombosis and Haemostasis-Scientific and Standardization Committee annual meetings. The pharmacokinetic, safety and efficacy data for longacting recombinant products are reviewed, with a focus on recombinant factor IX albumin fusion protein (rIX-FP) and rVIII-SingleChain. This overview also provides a guide for managing a patient's switch to long-acting products. Expert opinion: Long-acting products may allow patients to maintain or decrease bleeding rates whilst increasing their dosing interval, which may in turn reduce the burden on patients and caregivers. When switching patients to long-acting products health-care professionals should provide balanced and thorough education to the patient, whilst supporting their emotional well-being. Regimens should address patients' needs and goals but should also be guided by clinical phenotype and pharmacokinetic assessment. Follow-up should assess safety concerns, bleeding rates, joint health and the impact of the regimen on patients' lifestyle.

show abstract

Section: Factors To Address Before Switching Patientsmentioning

confidence: 99%

Section: Factors To Address Before Switching Patientsmentioning

confidence: 99%

Switching patients in the age of long-acting recombinant products?

Escobar¹,

Santagostino

Mancuso

et al. 2019

Expert Review of Hematology

View full text Add to dashboard Cite

show abstract

“…Inevitably, much of the work of managing the process of switching products falls to specialist haemophilia nurses [4] . However, there has been little in the way of formal assessment of the additional workload that tender-mandated factor switches impose on haemophilia nurses, or the hidden cost that this incurs.…”

mentioning

confidence: 99%

Switching factor products: nurses’ experience with NovoEight

Pollard

Khair²,

Holland³

2020

The Journal of Haemophilia Practice

View full text Add to dashboard Cite

AbstractHaemophilia nurses in the UK are instrumental in supporting people with haemophilia in self-management, including managing treatment options, recording treatment use and understanding the budgetary impact of prescribing practice. The widespread use of prophylaxis identified haemophilia as a high cost disorder to treat, resulting in a financially successful national tendering process with increased scrutiny of clotting factor use at both individual and haemophilia treatment centre level. The UK tenders, undertaken at a national level every three years, have ensured access to current and new therapies at the most cost-effective price through economies of scale in committing to purchase large volumes from suppliers.In the 2018 tendering round, NovoEight® (NovoNordisk) was added to the prescribing list and other recombinant factors were withdrawn, resulting in changes in prescribing for individual people with haemophilia. This ‘switching’ process is not uncommon in the UK, where national tenders have been in place since 2004. However, the unseen additional workload for nurses, driven by the demands of timely switching to meet product volumes and contracts, has never been captured. During the 2018 switch we interviewed 11 nurses and one operational manager from haemophilia centres across the UK to identify the barriers and facilitators to instigating this change.Ultimately the switching was completed in a timely manner, demonstrating significant cost reductions for factor concentrates. The unseen workload of the nurse – identifying which patients should have their product switched, discussion with and education of patients/families, adjusting prescriptions for home delivery of clotting factor concentrates and stock management and control to avoid waste, and organising the necessary additional clinic visits – was identified and costed based on salary per hour. Nurses remained positive that they were able to undertake this additional role but recognised that, with no specific national guidance regarding product choice, there may have inevitably been differences in approach between treatment centres.

show abstract

Switching factor products: selecting patients and managing the process

Cited by 2 publications

References 14 publications

Switching patients in the age of long-acting recombinant products?

Switching patients in the age of long-acting recombinant products?

Switching factor products: nurses’ experience with NovoEight

Contact Info

Product

Resources

About